In cell viability assays, metastatic melanoma cell lines with ILF2 knockdown had increased sensitivity to TMZ (p < .0001, Figure 5C), while metastatic melanoma cell lines with ILF2‐OV showed increased resistance to TMZ (p < .0001, Figure 5D). The gene discussed is ILF2; the disease is melanoma.